Voucher Program Extended for Arthritis Drug

Published Online: Saturday, January 1, 2005

The Trial Script voucher program for Rheumatrex Dose Pack (methotrexate sodium tablets) has been extended to August 2005. Rheumatrex, manufactured by STADA Pharmaceuticals, Inc, is a once-weekly disease-modifying antirheumatic drug for rheumatoid arthritis.

In the voucher program, patients receive a free 1-month trial supply of Rheumatrex in any weekly dosage available (5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). Physicians affix the voucher to the back of the prescription form. The patients activate the voucher by calling a toll-free number. Transactions are electronically processed through drug utilization programs, which may detect potential drug interactions.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues